Compare Futu Holdings Ltd (FUTU) vs Moderna, Inc. (MRNA) Price & Performance

FUTU Holdings trades at $98.13, up 1.85% with a bullish technical signal despite mixed earnings. The company shows strong fundamentals with 2025 revenue of $22.85B and net income of $11.34B, supported by robust profitability margins. However, recent quarterly earnings misses and ongoing securities class action lawsuits create significant headwinds.

While valuation metrics appear reasonable with P/E of 10.98 and analyst consensus leaning bullish (58% buy ratings), investors face substantial legal and regulatory risks. The stock's near-term trajectory will depend on Q2 2026 earnings results and resolution of multiple class action lawsuits alleging securities fraud violations.

Moderna (MRNA) trades at $67.44, showing modest daily gains amid a bullish technical signal. The company continues to beat earnings expectations despite reporting significant net losses, with revenue declining from pandemic peaks to $1.92B in 2025. Recent positive developments include EU RSV vaccine contracts, Phase 1 cancer trial initiation, and FDA advisory panel support for its mRNA flu vaccine, driving recent stock momentum.

While Moderna's pipeline expansion beyond COVID-19 shows promise with oncology and rare disease applications, substantial financial risks persist with negative profit margins and cash burn. Analyst consensus remains cautious with a $49 price target below current levels, reflecting concerns about revenue sustainability versus pipeline execution risks and valuation metrics.